Arrowhead Gains CHMP Nod for REDEMPLO in Rare Disease

Pasadena, California | April 24, 2026

Arrowhead Pharmaceuticals has achieved a major regulatory milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of REDEMPLO® (plozasiran) for the treatment of familial chylomicronemia syndrome (FCS). This development positions the company closer to securing European Commission marketing authorization, potentially introducing a first-in-class siRNA therapy for this rare and life-threatening lipid disorder.

Breakthrough siRNA Therapy Targets Severe Triglyceride Disorders

REDEMPLO® (plozasiran) is a small interfering RNA (siRNA)-based therapy designed to significantly reduce elevated triglyceride levels in adult patients with FCS, a rare genetic condition characterized by extremely high triglycerides and a high risk of acute pancreatitis. The disease affects approximately 1 to 13 individuals per million globally, often leading to recurrent, potentially fatal complications and reduced quality of life.

Unlike conventional treatments, REDEMPLO offers a novel mechanism of action through RNA interference, targeting the underlying biological pathways responsible for lipid metabolism. Notably, the therapy does not require genetic confirmation of FCS, expanding treatment access to a broader patient population and addressing a significant unmet clinical need.

If approved, REDEMPLO would become the first and only siRNA medicine authorized in the European Union for both genetically confirmed and clinically diagnosed FCS patients, marking a transformational advancement in precision medicine and rare disease therapeutics.

Phase 3 Data Demonstrates Strong Efficacy and Safety Profile

The CHMP recommendation is supported by robust clinical evidence from the Phase 3 PALISADE study, where REDEMPLO demonstrated a median triglyceride reduction of approximately 80% from baseline, a clinically meaningful outcome for patients with severe hypertriglyceridemia. Additionally, the study reported significantly fewer cases of acute pancreatitis among treated patients compared to placebo, highlighting both efficacy and potential long-term clinical benefit.

These results underscore the therapeutic potential of Arrowhead’s proprietary TRiM™ platform, which enables targeted delivery of RNAi therapies to specific tissues. The platform’s ability to modulate gene expression with precision represents a growing trend in next-generation drug development, particularly for metabolic and genetic disorders.

Furthermore, REDEMPLO has already received regulatory approvals in the United States, Canada, and China, reinforcing confidence in its clinical profile and global applicability. The positive CHMP opinion therefore represents a key step toward harmonizing access to advanced therapies across major international markets.

Regulatory Outlook and Impact on Rare Disease Treatment

Following the CHMP’s recommendation, the European Commission is expected to issue a final decision in the second quarter of 2026, which could pave the way for commercialization across Europe. Approval would significantly enhance treatment options for patients with FCS, many of whom currently rely on dietary restrictions and limited pharmacological interventions.

This milestone highlights Arrowhead Pharmaceuticals’s transition toward becoming a commercial-stage biotech leader, leveraging its expertise in RNA interference technology to address complex diseases. It also reflects the broader industry shift toward gene-silencing therapies and precision medicine approaches, which are increasingly shaping the future of pharmaceutical innovation.

As regulatory momentum builds, REDEMPLO stands as a compelling example of how cutting-edge RNAi science can translate into real-world clinical impact, offering new hope for patients living with rare and challenging metabolic conditions.

Source: Arrowhead Pharmaceuticals press release